Bimagrumab Placebo

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

ObesityOverweight

Phase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Active, not recruitingNCT06643728

Eli Lilly and CompanyObesity, Overweight

Start: 2024-10-21End: 2027-01-01Updated: 2026-05-26

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

WithdrawnNCT06901349

Eli Lilly and CompanyObesity, Overweight

Start: 2025-05-23End: 2025-06-10Updated: 2025-09-24